MedTrace Logo

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

NCT04171141 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-01-16

Study results available
· View outcomes & findings →

Summary

A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors

Conditions

  • Gastrointestinal Tumors
  • Colorectal Adenocarcinomas
  • Gastric Adenocarcinomas
  • Esophageal Adenocarcinomas

Interventions

DRUG

PF-07062119

PF-07062119

DRUG

Anti-PD1

Anti-PD1 PF-06801591

DRUG

Anti-VEGF

Anti-VEGF IV (bevacizumab)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2023-11-28
Completion
2023-11-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04171141 on ClinicalTrials.gov